LOS ANGELES, CA--(Marketwire - May 02, 2011) - Genesis Biopharma, Inc. (OTCBB: GNBP), a biotechnology company developing targeted cancer therapies, today announced its Chairman and CEO, Anthony J. Cataldo, presented an overview of the Company’s therapeutic development programs at the Aegis Capital Emerging Growth Conference in Las Vegas.
Mr. Cataldo’s presentation included a discussion about the Company’s therapeutic antibody platform and emerging autologous cell therapy platform. Mr. Cataldo discussed the status of Genesis Biopharma’s anti-CD55 antibody (GBP-102) as a prospective therapy for the treatment of ovarian cancer and gastrointestinal stomach tumors (GIST). Also discussed was an analysis of published adoptive cell therapy clinical trial results using autologous tumor infiltrating lymphocytes for the treatment of Stage IV metastatic melanoma.
“We are rapidly building out our therapeutic platforms,” stated Mr. Cataldo. “This includes conducting proof of preclinical concept experiments for GBP-102 at the University of Nottingham under the direction of Professor Lindy Durrant. Moving aggressively to establish our emerging autologous cell therapy program, we hope to conclude discussions in the near future with a major CRO for the manufacture of our autologous cell therapy product so that we may begin our pilot-stage clinical trial.”
Investors interested in viewing the full the presentation slide show may do so as of Tuesday, May 3rd at: www.genesis-biopharma.com.
About Genesis Biopharma, Inc.
Genesis Biopharma, Inc. is a development-stage biotechnology company engaged in the development of targeted cancer therapies. For more information about the company, visit www.genesis-biopharma.com.
Forward-Looking Statements
The foregoing press announcement contains forward-looking statements that can be identified by such terminology as “expect,” “potential,” “suggests,” “bodes,” “may,” “should,” “could” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management’s expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company’s ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as of the date they are made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
Contact:
Investor Contact:
Laurel Moody
Corporate Profile, LLC
646-810-0608
Digg this
Bookmark with del.icio.us
Add to Newsvine
Technorati: 
